1 Sep 2022
i-Cordis Receives SBIR Phase II Funding to Develop Treatment for Heart Failure with Preserved Ejection Fraction
Author: admintech | Filed under: Press ReleaseBALTIMORE, Sept. 1, 2022 /PRNewswire/ — i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential…